Jiangxi Biotech (06915) announced interim results, net profit of 14.366,000 yuan, a year-on-year decrease of 61%

According to the Zhitong Finance App, Jiangxi Biotech (06915) announced its 2026 interim results, with revenue of 83.3 million yuan, a year-on-year decrease of about 16.5%; R&D expenditure of 11 million yuan, an increase of 18.6%; net profit of 14.366 million yuan, a year-on-year decrease of 61%; and profit of 0.05 yuan per share.

According to the announcement, changes in performance were mainly affected by a combination of the following factors: (i) increased R&D expenses; (ii) adjustments to relevant national tax policies; (iii) reduced investment income; (iv) increased depreciation of fixed assets; and (v) one-time listing expenses. Among them, R&D expenses are mainly used to promote innovation pipeline development and platform technology upgrades, providing strong support for medium- to long-term R&D transformation and sustainable growth.

Excluding one-time items such as listing expenses and tax rate compensation, adjusted net profit for the reporting period was approximately RMB 38.7 million, a decrease of 21.7% compared to the same period last year. The Group continues to enhance its performance and management resilience through collaboration between ampoules and xillin bottles and continuous expansion of the terminal market. On the domestic side, Xilin bottle people used TAT products to complete the Internet connection of pharmaceutical procurement platforms in 32 provinces and cities in 26 provinces and cities; overseas, the Group signed a total of about 6.859 million orders during the period, with a contract amount of about 27.4 million yuan. As of June 30, 2026, the Group's cash and cash equivalents were approximately $408 million.